ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN)

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2013–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	—	4	1
2024	—	4	1
2023	—	5	2
2022	—	10	2
2021	—	8	2
2020	—	8	2
2019	—	9	2
2018	—	8	2
2017	—	8	2
2016	—	10	2
2015	—	4	1
2014	—	4	1
2013	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
KOUNTOUPES DENHAM CARR & REID, LLC	—	41
CAPITOL HILL CONSULTING GROUP	—	44

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	83
SENATE	83
Health & Human Services, Dept of (HHS)	18
White House Office	17
Office of Management & Budget (OMB)	10
Executive Office of the President (EOP)	2
Office of the Vice President of the United States	2
Transportation, Dept of (DOT)	2
Vice President of the U.S.	2
Federal Aviation Administration (FAA)	1
Natl Economic Council (NEC)	1
U.S. Trade Representative (USTR)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	85
Medicare/Medicaid	Medicare/Medicaid	80
Trade (domestic/foreign)	Trade (domestic/foreign)	54
Pharmacy	Pharmacy	53
Copyright/Patent/Trademark	Copyright/Patent/Trademark	24
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	16
Budget/Appropriations	Budget/Appropriations	16
Defense	Defense	3
Government Issues	Government Issues	2
Indian/Native American Affairs	Indian/Native American Affairs	2
Aviation/Airlines/Airports	Aviation/Airlines/Airports	2

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 43119th Congress

Skinny Labels, Big Savings Act

2025 · fourth_quarter · Firm: CAPITOL HILL CONSULTING GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues S. 43, Skinny Labels, Big Savings Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 43

H.R. 2853117th Congress

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021

2022 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2853

S. 3799117th Congress

PREVENT Pandemics Act

2022 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 3799

H.R. 2853117th Congress

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021

2022 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in user fees legislation.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2853

Show 21 more cited filings

S. 3799117th Congress

PREVENT Pandemics Act

2022 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in user fees legislation.

Client expense: — · Firm income: $60,000

Matched citations: S. 3799

H.R. 2853117th Congress

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021

2022 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in H.R. 7667, the Food and Drugs Amendments to 2022, and S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2853

H.R. 7667117th Congress

Food and Drug Amendments of 2022

2022 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in H.R. 7667, the Food and Drugs Amendments to 2022, and S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 7667

S. 3799117th Congress

PREVENT Pandemics Act

2022 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in H.R. 7667, the Food and Drugs Amendments to 2022, and S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 3799

S. 4348117th Congress

FDASLA Act of 2022

2022 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in H.R. 7667, the Food and Drugs Amendments to 2022, and S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 4348

H.R. 2853117th Congress

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021

2022 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA).

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2853

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

General education about the generic and biosimilar pharmaceutical industry, including issues related to pricing and access. Issues related to the pharmaceutical supply chain. Issues related to the drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA).

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the Medicaid Generics Penalty. Issues related to Medicare Part D. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

S. 3799117th Congress

PREVENT Pandemics Act

2022 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA).

Client expense: — · Firm income: $60,000

Matched citations: S. 3799

H.R. 153117th Congress

Protecting Consumer Access to Generic Drugs Act of 2021

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021, H.R. 2815, the BIOSIM Act, and H.R. 2869, Increasing Access to Biosimilars Act of 2021. Issues related to pharmaceutical patents, including H.R. 153, Protecting Consumer Access to Generic Dugs Act of 2021. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 153

H.R. 2815117th Congress

BIOSIM Act

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021, H.R. 2815, the BIOSIM Act, and H.R. 2869, Increasing Access to Biosimilars Act of 2021. Issues related to pharmaceutical patents, including H.R. 153, Protecting Consumer Access to Generic Dugs Act of 2021. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2815

H.R. 2853117th Congress

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021, H.R. 2815, the BIOSIM Act, and H.R. 2869, Increasing Access to Biosimilars Act of 2021. Issues related to pharmaceutical patents, including H.R. 153, Protecting Consumer Access to Generic Dugs Act of 2021. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2853

H.R. 2868117th Congress

Protecting Access to Affordable Medicines Act of 2021

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the Medicaid Generics Penalty, including H.R. 2868, protecting Access to Affordable Medicines Act of 2021. Issues related to Medicare Part D. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2868

H.R. 2869117th Congress

Increasing Access to Biosimilars Act of 2021

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021, H.R. 2815, the BIOSIM Act, and H.R. 2869, Increasing Access to Biosimilars Act of 2021. Issues related to pharmaceutical patents, including H.R. 153, Protecting Consumer Access to Generic Dugs Act of 2021. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2869

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021, H.R. 2815, the BIOSIM Act, and H.R. 2869, Increasing Access to Biosimilars Act of 2021. Issues related to pharmaceutical patents, including H.R. 153, Protecting Consumer Access to Generic Dugs Act of 2021. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

General education about the generic and biosimilar pharmaceutical industry, including issues related to pricing and access. Issues related to the pharmaceutical supply chain. Issues related to the drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2021 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the Medicaid Generics Penalty, including H.R. 2868, protecting Access to Affordable Medicines Act of 2021. Issues related to Medicare Part D. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 1319117th Congress

American Rescue Plan Act of 2021

2021 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars. Issues related to supply chains for generic medicines. Issues related to the implementation of H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021. Issues related to the implementation of H.R. 1319, The American Rescue Plan. Issues related to drug pricing and public health measures of H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1319

H.R. 1319117th Congress

American Rescue Plan Act of 2021

2021 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to generic pharmaceuticals and biosimilars, including H.R. 2853, BLOCKING Act of 2021. Reimbursement rate for biosimilars. Issues related to the implementation of H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021. Issues related to the implementation of H.R. 1319, The American Rescue Plan. Issues related to the pharmaceutical supply chain and domestic manufacturing. Issues related to H.R. 2815, the BIOISM Act and H.R. 2869, Increasing Access to Biosimilars Act of 2021. Issues related to the modernization of prescribing information. Issues related to pharmaceutical patents, including H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021. Issues related to H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1319

H.R. 133117th Congress

David’s Law

2021 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC

Open original LDA filing ↗

Cited source text and reported amounts

General education about the generic and biosimilar pharmaceutical industry. Issues related to affordability, including the pricing of pharmaceuticals and access to generics and biosimilars. Issues related to supply chains for generic medicines. Issues related to the implementation of H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021. Issues related to the implementation of H.R. 1319, The American Rescue Plan. Issues related to drug pricing and public health measures of H.R. 5376, the Build Back Better Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 133

Source: Senate LDA

ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) — Lobbying Disclosure | Poliscope